Valneva Provides Update on Chikungunya Vaccine IXCHIQ
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of…
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or…
React19 Launches This Is Our Shot Campaign as U.S. Vaccine Injury Victims Continue to Go Unheard and Uncompensated
SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- As the federal…
BlueWillow Biologics Intranasal Bird Flu Vaccine Shows Signs of Broad Immune Response in Phase I Clinical Trial Published in Nature Communications
ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc.,…
Award-Winning Film An Inconvenient Study Sparks Global Debate on Vaccine Safety and Chronic Disease
AUSTIN, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The award-winning film An Inconvenient…
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against…
Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University of Tbingen
TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT)…
Valneva Announces Lifting of European Medicines Agencys Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ in Elderly
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext…
